We are live on
!
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
129.82%
This Fund
S&P 500
This Quarter
Est. Return
+7.76%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$105M
AUM Growth
–
Cap. Flow
+$129M
Cap. Flow
% of AUM
122.84%
Top 10 Holdings %
Top 10 Hldgs %
81.01%
Holding
25
New
25
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$24.9M |
| 2 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
+$18.7M |
| 3 |
Enliven Therapeutics
ELVN
|
+$12.1M |
| 4 |
Abercrombie & Fitch
ANF
|
+$11.2M |
| 5 |
Tilly's
TLYS
|
+$10.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 64.73% |
| 2 | Consumer Discretionary | 22.48% |
| 3 | Technology | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Abercrombie & Fitch
ANF
$4.33B
| $13.1M | 12.5% |
+571,117
| New | +$11.2M |
|
|
2
Enliven Therapeutics
ELVN
$3.63B
| $12.3M | 11.79% |
+754,444
| New | +$12.1M |
|
|
3
Tilly's
TLYS
$122M
| $10.5M | 9.98% |
+1,154,844
| New | +$10.1M |
|
|
4
Disc Medicine
IRON
$2.81B
| $9.95M | 9.5% |
+500,000
| New | +$24.9M |
|
5
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
| $9.15M | 8.74% |
+100,000
| New | +$9.15M |
|
|
PRDS
6
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $8.23M | 7.86% |
+4,867,984
| New | +$6.17M |
|
|
CLYM
7
Climb Bio
CLYM
$720M
| $6.7M | 6.4% |
+1,825,134
| New | +$5.41M |
|
|
STSA
8
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $5.8M | 5.54% |
+6,440,000
| New | +$18.7M |
|
|
CARM
9
DELISTED
Carisma Therapeutics
CARM
| $5.01M | 4.79% |
+411,398
| New | +$4.32M |
|
|
ADVM
10
DELISTED
Adverum Biotechnologies
ADVM
| $4.1M | 3.91% |
+706,718
| New | +$5.36M |
|
11
Verrica Pharmaceuticals
VRCA
$95.5M
| $3.05M | 2.92% |
+111,061
| New | +$2.96M |
|
|
MTCR
12
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $2.76M | 2.64% |
+6,167,458
| New | +$2.55M |
|
|
LONA
13
LeonaBio Inc
LONA
$73.4M
| $2.27M | 2.16% |
+71,476
| New | +$2.25M |
|
14
Astrotech Corp
ASTC
$15.1M
| $2.2M | 2.1% |
+220,410
| New | +$2.48M |
|
|
ORKA
15
Oruka Therapeutics
ORKA
$5.01B
| $2.03M | 1.94% |
+71,521
| New | +$1.83M |
|
16
Richardson Electronics
RELL
$243M
| $2.03M | 1.94% |
+95,359
| New | +$2.16M |
|
17
Forte Biosciences
FBRX
$921M
| $1.46M | 1.4% |
+58,455
| New | +$1.5M |
|
18
Retractable Technologies
RVP
$20.7M
| $1.1M | 1.05% |
+668,575
| New | +$1.42M |
|
19
Milestone Pharmaceuticals
MIST
$154M
| $713K | 0.68% |
+180,000
| New | +$948K |
|
20
CalciMedica
CALC
$11M
| $618K | 0.59% |
+88,282
| New | +$990K |
|
21
Lisata Therapeutics
LSTA
$31.9M
| $617K | 0.59% |
+243,839
| New | +$894K |
|
22
Passage Bio
PASG
$15.8M
| $466K | 0.44% |
+16,873
| New | +$426K |
|
23
Adicet Bio
ACET
$76.8M
| $268K | 0.26% |
+1,875
| New | +$468K |
|
|
SPRB
24
Spruce Biosciences
SPRB
$122M
| $243K | 0.23% |
+2,958
| New | +$248K |
|
|
ELEV
25
DELISTED
Elevation Oncology
ELEV
| $38K | 0.04% |
+39,963
| New | +$40.6K |
|
Similar funds
AIS
BWM
TI
CFG
IWA
PFO
HCWM
BCM
BML Capital Management's Q4 2022 Portfolio in Review
Q4 2022 is the first quarter with a 13F filing on record for BML Capital Management, which disclosed 25 positions worth $105M. Its ten largest holdings account for 81% of the portfolio.
Its largest position is Disc Medicine: 500,000 shares worth $9.95M.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, followed by Consumer Discretionary and Technology.
- BML Capital Management's largest Q4 2022 buy was Disc Medicine: 500,000 shares worth $9.95M.
- BML Capital Management's ten largest holdings make up 81% of its $105M portfolio in Q4 2022.
- BML Capital Management disclosed 25 positions in Q4 2022, its first 13F filing on record.
Based on BML Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.